Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Lymphoma 50Breast Neoplasms 39Leukemia 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Multiple Myeloma 19Neuroblastoma 18Burkitt Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 12Sarcoma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 10Hodgkin Disease 10Central Nervous System Neoplasms 9Rhabdomyosarcoma 8Medulloblastoma 8Brain Neoplasms 7Wilms Tumor 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Inflammatory Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Ovarian Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Malignant mesenchymal tumor 4Ganglioneuroblastoma 4Dendritic Cell Sarcoma, Interdigitating 4

Interventions

Cyclophosphamide 3carfilzomib 2Dexamethasone 2deltacortene 1daratumumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Disease × Cyclophosphamide × Clear all
NCT01857115 2024-11-13

wCCyd

European Myeloma Network B.V.

Phase 1/2 Completed
63 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02204241 2023-07-03

CCD

European Myeloma Network B.V.

Phase 1/2 Completed
36 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡